Enacting the "Defense of affordable prescriptions act" to prohibit certain discriminatory actions related to reimbursement of entities participating in the federal 340B drug pricing program.
Impact
The impact of SB521 is substantial, as it addresses issues related to how health insurers and third-party payors manage pharmacy reimbursements for entities participating in the 340B program. It is designed to ensure that 340B-covered entities are not adversely affected by policies that impose additional costs or restrictions not faced by other pharmacies. This legislation aims to enhance healthcare access by preventing discrepancies in drug costs that may hinder the availability of essential medications.
Summary
Senate Bill 521, known as the Defense of Affordable Prescriptions Act, aims to impose restrictions on pharmacy benefit managers and health insurers regarding the reimbursement practices for entities participating in the federal 340B drug pricing program. This bill seeks to prohibit certain discriminatory actions towards these entities that may currently result in lower reimbursement rates for 340B drugs compared to non-340B drugs. The intent behind this legislation is to support 340B-covered entities, which play a critical role in providing affordable medications to underserved populations.
Contention
Despite its benefits, SB521 may face contention from health insurers and pharmacy benefits managers, who argue that such restrictions could complicate their ability to manage drug prices and contracts effectively. There may be concerns that the bill could lead to increased costs for insurers and ultimately for consumers. The balancing act between supporting affordable healthcare through the 340B program and ensuring sustainable insurance practices is likely to be a significant point of debate as SB521 moves through the legislative process.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.
Requiring certain 340B entities to report annually to the Kansas department of insurance on certain costs, savings and payments made under the federal 340B drug pricing program.